Benitec Biopharma Files 8-K Report
Ticker: BNTC · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Benitec Biopharma filed a routine 8-K, nothing major disclosed yet.
AI Summary
On July 15, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the filing of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates ongoing regulatory compliance and reporting by Benitec Biopharma Inc. to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for disclosure and exhibits, not indicating any immediate negative or positive material events.
Key Numbers
- 001-39267 — SEC File Number (Identifies the company's filing history with the SEC.)
- 241118051 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- July 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
FAQ
What specific items are being disclosed or filed as exhibits in this 8-K report?
The filing indicates 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' as items being reported, but the specific content of these items is not detailed in the provided excerpt.
What is the principal business address of Benitec Biopharma Inc.?
The principal executive offices are located at 3940 Trust Way, Hayward, California, 94545.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated July 15, 2024.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Standard Industrial Classification (SIC) code for Benitec Biopharma Inc.?
The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-07-15 17:18:32
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
Filing Documents
- d819205d8k.htm (8-K) — 25KB
- d819205dex991.htm (EX-99.1) — 25KB
- g819205g0715153002822.jpg (GRAPHIC) — 3KB
- g819205g0715153003127.jpg (GRAPHIC) — 36KB
- g819205g0715153003372.jpg (GRAPHIC) — 19KB
- g819205g0715153003638.jpg (GRAPHIC) — 20KB
- g819205g0715153003859.jpg (GRAPHIC) — 20KB
- g819205g0715153004093.jpg (GRAPHIC) — 23KB
- g819205g0715153004317.jpg (GRAPHIC) — 19KB
- 0001193125-24-179108.txt ( ) — 367KB
- bntc-20240715.xsd (EX-101.SCH) — 3KB
- bntc-20240715_lab.xml (EX-101.LAB) — 17KB
- bntc-20240715_pre.xml (EX-101.PRE) — 11KB
- d819205d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: July 15, 2024 /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer